A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) - CANTATA

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) - CANTATA

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs CB 839 (Primary) ; Cabozantinib
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms CANTATA
  • Sponsors Calithera Biosciences
  • Most Recent Events

    • 02 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 08 Mar 2018 According to a Calithera Biosciences media release, this trial is planned to begin in the second quarter of 2018 and it is expected to take approximately two years to reach the primary endpoint analysis of progression free survival.
    • 08 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top